New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

PURPOSE: HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify pa...

Descripción completa

Detalles Bibliográficos
Autores principales: MacNeil, Ian A., Burns, David J., Rich, Benjamin E., Soltani, Sajjad M., Kharbush, Samantha, Osterhaus, Nicole G., Sullivan, Brian F., Hawkins, Douglas M., Pietruska, Jodie R., Laing, Lance G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039866/
https://www.ncbi.nlm.nih.gov/pubmed/32036454
http://dx.doi.org/10.1007/s00432-020-03144-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039866/
https://www.ncbi.nlm.nih.gov/pubmed/32036454
http://dx.doi.org/10.1007/s00432-020-03144-7

Ejemplares similares